Sekar Kathiresan (Verve)
January 19, 2021 07:26 AM ESTUpdated 09:22 AM
Financing
Cell/Gene Tx

'Bluest of blue-chip in­vestors' pump $94M in­to Sekar Kathire­san's quest to bring CRISPR to the heart

Amber Tong

Go­ing in­to his first JP Mor­gan con­fer­ence, Sekar Kathire­san had some ma­jor news to share. His am­bi­tious car­dio­vas­cu­lar-fo­cused start­up, Verve Ther­a­peu­tics, had des­ig­nat­ed the PC­SK9 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times